Promises
3 promises
Promise Tracker
3 delivered, 0 close, 0 missed.
View Promises →
Fortis Healthcare Limited — Q1 FY25
Fortis Healthcare delivered a strong Q1 FY25 with consolidated revenue of INR 1,859 crore (+12.2% YoY) and EBITDA of INR 343 crore (+25.5% YoY), driven by the hospital business which grew 14.4% and expanded margins by 330bps to 18.5%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare delivered a strong Q1 FY25 with consolidated revenue of INR 1,859 crore (+12.2% YoY) and EBITDA of INR 343 crore (+25.5% YoY), driven by the hospital business which grew 14.4% and expanded margins by 330bps to 18.5%. The diagnostics segment (Agilus) remained flat at INR 343 crore, with margins pressured by rebranding costs and government provisions. Hospital occupancy improved to 67% (vs 64% YoY) and ARPOB rose 9.7% to INR 2.41 crore. Key growth areas included neurosciences (+23%) and oncology (+22%). Management guided for hospital EBITDA margins above 20% for FY25, supported by brownfield expansions and cost initiatives. Agilus expects to return to industry growth by next year. Risks include margin pressure from payer mix shift and ongoing legal costs from the Daiichi dispute.
फोर्टिस हेल्थकेयर ने पहली तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 1,859 करोड़ रुपये रही, जो पिछले साल से 12.2% ज्यादा है। मुनाफा (EBITDA) 343 करोड़ रुपये रहा, जो 25.5% बढ़ा। अस्पताल का कारोबार 14.4% बढ़ा और मुनाफा मार्जिन 18.5% हो गया। डायग्नोस्टिक्स (एगिलस) का कारोबार 343 करोड़ रुपये पर स्थिर रहा, क्योंकि रीब्रांडिंग और सरकारी खर्चों से मार्जिन पर दबाव पड़ा। अस्पतालों में मरीजों की संख्या 67% रही (पिछले साल 64%) और प्रति बिस्तर कमाई 9.7% बढ़कर 2.41 करोड़ रुपये हो गई। न्यूरोसाइंसेज (+23%) और ऑन्कोलॉजी (+22%) में अच्छी बढ़त रही। कंपनी का लक्ष्य इस साल अस्पताल का मार्जिन 20% से ऊपर रखना है। एगिलस अगले साल तक उद्योग की रफ्तार पकड़ लेगा। जोखिमों में मरीजों के भुगतान में बदलाव और दाइची विवाद से कानूनी खर्च शामिल हैं।
Promises3 met · 0 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Payer mix shift impacting margins
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Hospital Occupancy
67%
+3pp YoY
Occupancy improved from 64% in Q1 FY24, driven by higher patient volumes across key facilities.
ARPOB (Annual Revenue Per Occupied Bed)
INR 2.41 crore
+9.7% YoY
Revenue per occupied bed increased, fueled by growth in high-value specialties like oncology and neurosciences.
Robotic Surgeries Growth
59%
+59% YoY
Number of robotic surgeries surged 59% YoY, reflecting adoption of advanced surgical technologies.
Digital Channel Revenue Share
30%
+7pp YoY
Revenue from digital channels contributed 30% of hospital revenue, up from 23% in Q1 FY24.
What Changed vs Last Quarter
NEW
Agilus rebranding spend of INR 50 crore in FY25
Agilus plans to spend approximately INR 50 crore on rebranding expenses this fiscal year, which will be treated as one-off costs.
NEW
Manesar 350-bed facility to be operational in Q2 FY25
The acquired Manesar facility is expected to start operations in the ongoing quarter, initially with 100 beds, ramping up to full capacity over 18 months.
NEW
Agilus to return to industry growth by next year
Management expects Agilus to consolidate during FY25 and return to industry-level growth in FY26, driven by brand recovery and network expansion.
UPDATED
Hospital EBITDA margin target of 20%+ for FY25
Management reiterated guidance for hospital business EBITDA margins to exceed 20% for the full year, despite Q1 margin of 18.5% impacted by one-offs and mix.
DROPPED
Brownfield bed addition of ~700 beds in FY25
Includes 50 beds each at Faridabad and Kalyan, 100 beds at Manesar (Q2), 100 beds at Kolkata (Q1), and beds at BG Road (Q2).
DROPPED
Medium-term ARPOB growth of 4-5%
ARPOB growth expected to moderate to 4-5% in medium term from 10.8% in FY24, driven by 2-2.5% price increases and case mix improvement.
DROPPED
Agilus put option resolution by Q2 FY25
Management expects to finalize the put option (due Oct 2024) by August-September 2024, with options including IPO revival or buyout via debt/equity.
NEW RISK
Payer mix shift impacting margins
Increase in scheme business (CGHS/ECHS) and higher share of lower-margin specialties (ortho, onco) compressed hospital EBITDA margins by ~2% in Q1.
NEW RISK
Agilus underperformance and brand transition drag
Diagnostics revenue remained flat YoY, with margins declining due to rebranding costs and government provisions; recovery may take longer than expected.
NEW RISK
Legal costs from Daiichi dispute to persist
Legal costs related to the Daiichi litigation are expected to remain high this year, with potential appeals adding uncertainty.
NEW RISK
Geopolitical risks impacting medical travel
Recent developments in Bangladesh and Israel may affect international patient flows, though management expects no material impact.
RISK GONE
Agilus put option liability could strain balance sheet
If PE investor exercises put option, Fortis may need to raise ~₹1,200-1,300 crore, potentially via debt or equity, impacting leverage or dilution.
RISK GONE
Ongoing legal cases and brand litigation costs
Annual legal costs of ₹30-50 crore related to legacy issues (brand, forensic audit) may persist until resolution; Supreme Court stay on promoter shareholding dismissed.
RISK GONE
Diagnostics business recovery slower than expected
Agilus volumes grew only 0.6% in Q4 despite rebranding; competitive pressures and government business provisions may delay margin recovery.
RISK GONE
CGHS rate revision uncertainty
Government revenue (20% of hospital) may benefit from CGHS rate revision, but timing and quantum are uncertain; not factored into guidance.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
Mentioned in Q1 FY24, Q2 FY24
Management identified potential delays in brownfield bed commissioning as a key risk to achieving FY25 margin targets.
Mentioned in Q1 FY24, Q2 FY24
Rapid growth in medical oncology (lower margin) relative to surgical oncology could cap margin expansion despite absolute EBITDA growth.
Mentioned in Q2 FY24, Q4 FY24
Annual legal costs of ₹30-50 crore related to legacy issues (brand, forensic audit) may persist until resolution; Supreme Court stay on promoter shareholding dismissed.
Fast read
Guidance and risk preview
Management reiterated guidance for hospital business EBITDA margins to exceed 20% for the full year, despite Q1 margin of 18.5% impacted by one-off...
Increase in scheme business (CGHS/ECHS) and higher share of lower-margin specialties (ortho, onco) compressed hospital EBITDA margins by ~2% in Q1.
View Risks →